New Key Statistics Module, Z-Score and F-Score
OTCPK:ENZN Key Ratios
Market Cap $ M | 5.37 |
Enterprise Value $ M | -42.20 |
P/E(ttm) | -- |
PE Ratio without NRI | -- |
Forward PE Ratio | -- |
Price/Book | 1.45 |
Price/Sales | -- |
Price/Free Cash Flow | 4.25 |
Price/Owner Earnings | -- |
Payout Ratio % | -- |
Revenue (TTM) $ M | -- |
EPS (TTM) $ | -0.002 |
Beneish M-Score | 0 |
10-y EBITDA Growth Rate % | -- |
5-y EBITDA Growth Rate % | -- |
y-y EBITDA Growth Rate % | -- |
EV-to-EBIT | 40.42 |
EV-to-EBITDA | 40.42 |
PEG | -- |
Shares Outstanding M | 74.21 |
Net Margin (%) | -- |
Operating Margin % | -- |
Pre-tax Margin (%) | -- |
Quick Ratio | 27.62 |
Current Ratio | 27.62 |
ROA % (ttm) | 2.92 |
ROE % (ttm) | 45.09 |
ROIC % (ttm) | -526.28 |
Dividend Yield % | -- |
Altman Z-Score | -- |
Piotroski F-Score | 5.00 |
Positive ROA | Y |
Positive CFROA | Y |
Higher ROA y-y | Y |
Cash flow > Earnings | N |
Lower Leverage y-y | Y |
Higher Current Ratio y-y | N |
Less Shares Outstanding y-y | Y |
Gross Margin Increase y-y | N |
Higher Asset Turnover y-y | N |
ENZN Number of Guru Trades
ENZN Volume of Guru Trades
Gurus Latest Trades with OTCPK:ENZN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
OTCPK:ENZN is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Enzon Pharmaceuticals Inc Insider Transactions
No Available Data
News about OTCPK:ENZN
Total 0- 1